Volume 24, Issue 5, Pages (November 2016)

Slides:



Advertisements
Similar presentations
Making Proteins in the Powerhouse B. Martin Hällberg, Nils-Göran Larsson Cell Metabolism Volume 20, Issue 2, Pages (August 2014) DOI: /j.cmet
Advertisements

Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.
Overview of Pyridine Nucleotides Review Series
Histone Acetylation Regulates Intracellular pH
Volume 57, Issue 1, Pages (January 2015)
Stopping the Clock with MYC
Rapamycin Suppresses Tumor Growth and Alters the Metabolic Phenotype in T-Cell Lymphoma  Wasakorn Kittipongdaja, Xuesong Wu, Justine Garner, Xiping Liu,
Type 3 Deiodinase in Hypoxia: To Cool or to Kill?
Volume 21, Issue 5, Pages (May 2015)
Why NAD+ Declines during Aging: It’s Destroyed
Volume 11, Issue 2, Pages (February 2005)
ATP Citrate Lyase Improves Mitochondrial Function in Skeletal Muscle
Volume 28, Issue 4, Pages (October 2015)
Volume 14, Issue 4, Pages (October 2011)
You Down With ETC? Yeah, You Know D!
Coming up for air: HIF-1 and mitochondrial oxygen consumption
Volume 24, Issue 5, Pages (November 2016)
Volume 59, Issue 3, Pages (August 2015)
Volume 51, Issue 2, Pages (July 2013)
Volume 23, Issue 3, Pages (March 2016)
Understanding the Intersections between Metabolism and Cancer Biology
Joseph A. Baur, Morris J. Birnbaum  Cell Metabolism 
Christian M. Metallo, Matthew G. Vander Heiden  Molecular Cell 
Ng Shyh-Chang, George Q. Daley  Cell Metabolism 
Volume 7, Issue 3, Pages (May 2014)
Hypoxic Regulation of Glutamine Metabolism through HIF1 and SIAH2 Supports Lipid Synthesis that Is Necessary for Tumor Growth  Ramon C. Sun, Nicholas C.
Volume 23, Issue 4, Pages (April 2016)
Anupama Sahoo, Sanjaya K. Sahoo, Piyush Joshi, Bongyong Lee, Ranjan J
Volume 162, Issue 3, Pages (July 2015)
Metabolic Flux and the Regulation of Mammalian Cell Growth
Volume 27, Issue 2, Pages e5 (February 2018)
Volume 22, Issue 4, Pages (October 2015)
Volume 55, Issue 2, Pages (July 2014)
Volume 23, Issue 6, Pages (June 2016)
Volume 22, Issue 13, Pages (March 2018)
The Nurture of Tumors Can Drive Their Metabolic Phenotype
Volume 162, Issue 3, Pages (July 2015)
Waste Not, Want Not: Lactate Oxidation Fuels the TCA Cycle
Volume 61, Issue 2, Pages (January 2016)
Type 3 Deiodinase in Hypoxia: To Cool or to Kill?
Volume 25, Issue 4, Pages e7 (April 2018)
Volume 40, Issue 6, Pages e6 (March 2017)
Wissam Assaily, Samuel Benchimol  Cancer Cell 
Pyruvate as a Pivot Point for Oncogene-Induced Senescence
Volume 6, Issue 3, Pages (September 2007)
Volume 38, Issue 4, Pages (May 2010)
Biochemical Underpinnings of Immune Cell Metabolic Phenotypes
Volume 50, Issue 2, Pages (April 2013)
Volume 23, Issue 5, Pages (May 2016)
Volume 22, Issue 2, Pages (January 2018)
Volume 57, Issue 1, Pages (January 2015)
Volume 15, Issue 2, Pages (February 2012)
Volume 21, Issue 2, Pages (February 2015)
Volume 15, Issue 2, Pages (April 2016)
Volume 13, Issue 4, Pages (April 2011)
Circadian Rhythm Disruption Promotes Lung Tumorigenesis
Power Surge: Supporting Cells “Fuel” Cancer Cell Mitochondria
Volume 13, Issue 4, Pages (April 2011)
Volume 16, Issue 4, Pages (October 2012)
Linking DNA Damage, NAD+/SIRT1, and Aging
Yin Pun Hung, John G. Albeck, Mathew Tantama, Gary Yellen 
Shuai Jiang, Wei Yan, Shizhen Emily Wang, David Baltimore 
Volume 93, Issue 6, Pages e5 (March 2017)
Christopher D. Wiley, Judith Campisi  Cell Metabolism 
Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice  Jun Yoshino, Kathryn F. Mills,
Dengue Virus-Induced Autophagy Regulates Lipid Metabolism
Overcoming ATM Deficiency by Activating the NAD+/SIRT1 Axis
Volume 27, Issue 12, Pages e4 (June 2019)
Volume 25, Issue 11, Pages e4 (December 2018)
Tomohiro Tanaka, Yo-ichi Nabeshima  Cell Metabolism 
Presentation transcript:

Volume 24, Issue 5, Pages 716-727 (November 2016) Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin  Dan Y. Gui, Lucas B. Sullivan, Alba Luengo, Aaron M. Hosios, Lauren N. Bush, Nadege Gitego, Shawn M. Davidson, Elizaveta Freinkman, Craig J. Thomas, Matthew G. Vander Heiden  Cell Metabolism  Volume 24, Issue 5, Pages 716-727 (November 2016) DOI: 10.1016/j.cmet.2016.09.006 Copyright © 2016 Elsevier Inc. Terms and Conditions

Cell Metabolism 2016 24, 716-727DOI: (10.1016/j.cmet.2016.09.006) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 1 Pyruvate Suppresses the Anti-proliferative Effects of Metformin (A–D) Proliferation rates for A549, H1299, MDA-MB231, HeLa, and 143B cells in media treated with the indicated concentrations of metformin. Cells were cultured in DMEM (A), RPMI 1640 (B), DMEM without pyruvate (C), and RPMI 1640 supplemented with 1 mM pyruvate (D). Values denote mean ± SEM. n = 3. See also Figure S1. Cell Metabolism 2016 24, 716-727DOI: (10.1016/j.cmet.2016.09.006) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 2 Complex I Activity Is Dispensable When Exogenous Pyruvate Is Available to Act as an Electron Acceptor (A) Mitochondrial oxygen consumption of A549 cells following permeabilization by saponin, addition of pyruvate and malate, addition of either metformin or vehicle, and addition of antimycin as indicated. (B and C) Proliferation rates for A549 and HeLa cells treated with the indicated dose of complex I inhibitor rotenone in DMEM (B) or DMEM without pyruvate (C). (D) Schematic illustrating how oxygen allows cells to regenerate NAD+ from NADH via complex I activity and the site of action of complex I inhibitors. Exogenous pyruvate provides an alternate way to regenerate NAD+ through lactate dehydrogenase (LDH) activity. (E and F) Mitochondrial oxygen consumption rates of A549 (E) and HeLa (F) cells treated with the indicated concentrations of metformin and pyruvate. (G and H) Intracellular NAD+/NADH ratios of A549 (G) and HeLa (H) cells treated with the indicated concentrations of metformin and pyruvate. (I and J) Mitochondrial oxygen consumption rates of A549 (I) and HeLa (J) cells treated with the indicated concentrations of rotenone and pyruvate. (K and L) Intracellular NAD+/NADH ratios of A549 (K) and HeLa (L) cells treated with the indicated concentrations of rotenone and pyruvate. Values denote mean ± SEM. n = 5 (A, E, F, I, and J). n = 3 (B, C, G, H, K, and L). See also Figure S2. Cell Metabolism 2016 24, 716-727DOI: (10.1016/j.cmet.2016.09.006) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 3 Altering Cellular NAD+/NADH Ratio Titrates Dependency on Complex I Activity (A) Proliferation rates for A549, H1299, MDA-MB231, HeLa, and 143B cells treated with 1 mM metformin and supplemented with the indicated amounts of pyruvate. (B) Schematic illustrating how poly(ADP-ribose) polymerases (PARPs) consume NAD+. (C) Proliferation rates of A549 and HeLa cells treated with metformin at the indicated concentration in media supplemented with the indicated concentrations of the PARP inhibitor 3-aminobenzamide (3-AB). (D) Schematic illustrating how nicotinamide mononucleotide (NMN) supplementation can increase NAD+ synthesis by nicotinamide mononucleotide adenylyltransferase (NMNAT) activity. (E) Proliferation rates of metformin-treated A549 and HeLa cells supplemented with the indicated concentrations of NMN. (F) Schematic illustrating how duroquinone can oxidize NADH to yield NAD+ and durohydroquinone by the activity of NAD(P)H dehydrogenase, quinone 1 (NQO1). (G) Proliferation rates of metformin-treated A549 and HeLa cells supplemented with the indicated concentrations of duroquinone. Values denote mean ± SEM. n = 3. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. See also Figure S3. Cell Metabolism 2016 24, 716-727DOI: (10.1016/j.cmet.2016.09.006) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 4 NAD+/NADH Ratio Tracks with Proliferation Rate in Metformin-Treated Cells (A and B) Intracellular NAD+/NADH ratios (A) and proliferation rates (B) were measured after treatment with metformin at the indicated doses in A549 cells and HeLa cells. (C) Proliferation rates and NAD+/NADH ratios were plotted independent of metformin concentrations to determine the relationship between the NAD+/NADH ratio and proliferation rate in A549 cells and HeLa cells, respectively. Values denote mean ± SEM. n = 3. See also Figure S4. Cell Metabolism 2016 24, 716-727DOI: (10.1016/j.cmet.2016.09.006) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 5 Anti-proliferative Effects of Metformin Are Suppressed by Exogenous Aspartate (A) Intracellular aspartate levels were measured after treatment with metformin at the indicated doses in A549 cells. (B) Aspartate levels and NAD+/NADH ratios were plotted independent of metformin concentrations to determine the relationship between the NAD+/NADH ratio and aspartate levels in A549 cells. (C) Intracellular aspartate levels in A549 cells treated with the indicated doses of metformin and pyruvate. (D) Proliferation rates of A549 treated with the indicated doses of metformin and exogenous aspartate. (E) Normalized IMP/AMP ratio in A549 treated with the indicated doses of metformin and exogenous aspartate. Values denote mean ± SEM. n = 3. See also Figure S5. Cell Metabolism 2016 24, 716-727DOI: (10.1016/j.cmet.2016.09.006) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 6 Metformin Slows Tumor Growth and Decreases Intratumoral NAD+ and Aspartate Levels (A) A549 xenografts in nude mice were treated with vehicle or the indicated doses of metformin once a day by oral gavage. (B and C) Serum (B) and tumor metformin (C) concentrations measured in material from mice treated for 10 days at the indicated dose of metformin, with tissue harvested 2 hr after the last dose. (D and E) Relative intratumoral NAD+ (D) and aspartate (E) levels after 10 days of vehicle or metformin treatment at the indicated dose. Relative NAD+ and aspartate levels are shown as NAD+ and aspartate total ion counts (TIC) normalized to leucine TIC. Values denote mean ± SEM. ∗p < 0.05; ∗∗p < 0.01. See also Figure S6. Cell Metabolism 2016 24, 716-727DOI: (10.1016/j.cmet.2016.09.006) Copyright © 2016 Elsevier Inc. Terms and Conditions